To determine whether increased pericyte proportion is subsequent to high microvascular density, thus correlating with the reduced TMZ efficacy in GBMs, we performed immunofluorescence staining of the pericyte marker CD14622 and endothelial cell marker CD31 in malignant gliomas with TMZ treatment (Fig. 1d). The gene discussed is PECAM1; the disease is malignant glioma.